HemoGenyx Pharmaceuticals Plc (GB:HEMO) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
HemoGenyx Pharmaceuticals has successfully completed a crucial site initiation visit for its Phase I clinical trial of HG-CT-1, a promising treatment for relapsed/refractory acute myeloid leukemia (AML). This milestone sets the stage for patient recruitment and highlights the company’s commitment to developing innovative therapies for blood diseases with limited treatment options. The trial aims to explore the safety and potential of HG-CT-1, leveraging CAR-T cell therapy to improve outcomes for AML patients.
For further insights into GB:HEMO stock, check out TipRanks’ Stock Analysis page.